{
    "project_id": "170813",
    "broad_study_type": "trial",
    "narrow_study_type": "randomized_controlled_trial",
    "trial_phase": "3",
    "observational_timeframe": "N/A",
    "justification": "testing whether medically prescribed heroin is a safe and effective treatment that improves on currently available therapies",
    "data_type": "canadian",
    "ipd_used": "individual",
    "novelty_statement": "The ultimate goal of this research is to benefit both people with the most severe cases of heroin addiction as well as their communities.",
    "replication_study": "no",
    "target_population_size": "N/A",
    "age_range": "adults",
    "gender_focus": "women",
    "vulnerable_populations": "yes",
    "rare_disease": "no",
    "population_description": "long-term injection opiate users who do not benefit from available therapies",
    "intervention_category": "drug",
    "intervention_name": "diacetylmorphine (heroin) and hydromorphone",
    "control_type": "active_control",
    "dose_response": "no",
    "combination_therapy": "no",
    "personalized_medicine": "no",
    "primary_outcome": "treatment efficacy for opioid dependence",
    "primary_outcome_type": "clinical",
    "safety_focus": "yes",
    "quality_of_life": "yes",
    "biomarker_endpoints": "no",
    "time_to_event": "no",
    "composite_endpoint": "yes",
    "ai_machine_learning": "no",
    "digital_health": "no",
    "telemedicine": "no",
    "wearable_technology": "no",
    "big_data_analytics": "no",
    "blockchain": "no",
    "cost_effectiveness": "yes",
    "budget_impact": "yes",
    "health_technology_assessment": "yes",
    "resource_utilization": "yes",
    "productivity_outcomes": "yes",
    "implementation_science": "no",
    "policy_evaluation": "yes",
    "health_system_integration": "yes",
    "scalability_assessment": "no",
    "barrier_identification": "no",
    "adaptive_design": "no",
    "bayesian_methods": "no",
    "machine_learning_analysis": "no",
    "novel_biostatistics": "no",
    "patient_reported_outcomes": "yes",
    "real_world_evidence": "no",
    "industry_partnership": "no",
    "patient_engagement": "yes",
    "community_based": "yes",
    "indigenous_collaboration": "no",
    "international_collaboration": "no",
    "international_network": "no",
    "regulatory_pathway": "yes",
    "ethics_focus": "yes",
    "consent_innovation": "no",
    "data_sharing": "no",
    "therapeutic_area": "addiction",
    "disease_stage": "severe",
    "comorbidity_focus": "yes",
    "pandemic_related": "no",
    "environmental_health": "no",
    "social_determinants": "yes",
    "health_equity": "yes",
    "climate_health": "no",
    "urban_rural": "yes",
    "biobank_use": "no",
    "registry_linkage": "no",
    "cohort_establishment": "no",
    "platform_trial": "no",
    "study_duration": "long_term",
    "multicenter": "yes",
    "healthcare_setting": "outpatient",
    "disease_area": "opioid dependence, heroin addiction",
    "methodology_innovation": "double-blind randomized controlled trial comparing diacetylmorphine vs. hydromorphone for treatment-refractory opioid use disorder",
    "knowledge_translation_focus": "yes",
    "equity_considerations": "yes"
} 